Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2011 to 2025 of 7707 results

  1. Secukinumab biosimilar for treating plaque psoriasis TSID 11992

      Status ...

    Technology appraisal guidance
    Topic selection

  2. Zavegepant for treating acute migraine TSID 11998

    Awaiting development [GID-TA11527] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older TSID 11995

    Awaiting development [GID-TA11525] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy TSID 11996

    Awaiting development [GID-TA11526] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. The EOS 2D/3D imaging system (DG1)

    Evidence-based recommendations on the EOS 2D/3D imaging system for producing 2D and 3D images of the skeleton

    Diagnostics guidance
    Published
    26 October 2011
    View recommendations

    Sections for DG1

  6. moorLDI2-BI: a laser doppler blood flow imager for burn wound assessment (MTG2)

    Evidence-based recommendations on moorLDI2-BI: a laser doppler blood flow imager for burn wound assessment.

    Medical technologies guidance
    Last updated
    7 August 2017
    View recommendations

    Sections for MTG2

  7. Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]

    Awaiting development [GID-TA11116] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Ciclosporin ophthalmic solution for treating dry eyes after inadequate response to artificial tears TSID8472

      Status ...

    Technology appraisal guidance
    Topic selection

  9. Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833]

    Awaiting development [GID-TA10718] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]

    Awaiting development [GID-TA10717] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease TS ID 11991

    Awaiting development [GID-TA11518] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]

    In development [GID-TA11425] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. DCVax-L for treating glioblastoma [ID836]

    In development [GID-TA10143] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular or marginal zone lymphoma after 1 or more anti-CD20 treatments ID6413

    Awaiting development [GID-TA11488] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage ID6412 small-cell lung cancer TS ID 11975

    Awaiting development [GID-TA11497] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development